menu
    • menu

    Company profile for Crossject

    NEW Drugs in Dev: 3
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    All of Crossject's employees work every day as a team to develop innovative life-saving solutions and make them a reality for patients. Our approach to the administration of emergency medicines mobilizes not only our teams but also our industrial and financial partners to act on a patient life-saving mission across the world. From the solid foundation of its unmatched technology, Crossject aims to become the world's leading p...
    All of Crossject's employees work every day as a team to develop innovative life-saving solutions and make them a reality for patients. Our approach to the administration of emergency medicines mobilizes not only our teams but also our industrial and financial partners to act on a patient life-saving mission across the world. From the solid foundation of its unmatched technology, Crossject aims to become the world's leading pharmaceutical laboratory for emergency needle free auto-injectables.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    CrossjectFrance Flag
    Country
    Country
    France
    Address
    Address
    Parc MAZEN-SULLY, 6-8 rue Pauline Kergomard, Dijon, Bourgogne 21000
    Telephone
    Telephone
    +33 (0)3 80 54 98 50
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.crossject.com/en
    Linkedin
    Linkedin
    https://www.linkedin.com/company/crossject/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    SCOPE Summit

    SCOPE Summit

    Not Confirmed

    envelop Contact Supplier

    SCOPE Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Crossject Announce Initiation of Coverage of Stock by Portzamparc
    Crossject Announce Initiation of Coverage of Stock by Portzamparc

    02 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/02/3229950/0/en/CROSSJECT-announces-initiation-of-coverage-of-its-stock-by-Portzamparc-BNP-Paribas-Group.html

    GLOBENEWSWIRE
    02 Feb 2026
    Share Share
    Crossject Completes €5 Million Financing with Vatel Capital
    Crossject Completes €5 Million Financing with Vatel Capital

    14 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/14/3188556/0/en/CROSSJECT-completes-5-million-financing-with-Vatel-Capital.html

    GLOBENEWSWIRE
    14 Nov 2025
    Share Share
    Crossject Secures More Barda Funding For Zepizure® FDA
    Crossject Secures More Barda Funding For Zepizure® FDA

    22 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/22/3153626/0/en/CROSSJECT-Secures-Additional-BARDA-Funding-for-the-Progressive-Developmental-and-FDA-Authorization-of-the-ZEPIZURE-ZENEO-Midazolam.html

    GLOBENEWSWIRE
    22 Sep 2025
    Share Share
    Crossject Remains Engaged During the Summer Break
    Crossject Remains Engaged During the Summer Break

    04 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/04/3126727/0/en/CROSSJECT-remains-engaged-during-the-summer-break.html

    GLOBENEWSWIRE
    04 Aug 2025
    Share Share
    CROSSJECT successful €5.7M capital increase with full extension
    CROSSJECT successful €5.7M capital increase with full extension

    24 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/24/3104583/0/en/CROSSJECT-announces-a-successful-capital-increase-of-5-7-million-following-full-exercise-of-the-extension-clause.html

    GLOBENEWSWIRE
    24 Jun 2025
    Share Share
    CROSSJECT progresses on ZEPIZURE® Junior for childhood epilepsy
    CROSSJECT progresses on ZEPIZURE® Junior for childhood epilepsy

    11 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/11/3097270/0/en/CROSSJECT-advances-on-the-development-of-ZEPIZURE-Junior-its-solution-for-epilepsy-crises-in-children.html

    GLOBENEWSWIRE
    11 Jun 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search